GUANGZHOU, China, April 18, 2026 /PRNewswire/ — On April 15, the 139th Canton Fair opened in Guangzhou. As one of the world’s largest trade events, it gathers global buyers and leading manufacturers. TAILG participated under “Tech TAILG. Leading Globally,” presenting its full lineup of flagship products and demonstrating strength in electric mobility and global development.

On the opening day, TAILG appeared with one of the largest booth areas in the exhibition hall. Visitor traffic remained high throughout the day. Buyers from Europe, the Americas, and other regions—including new and long-term partners—visited the booth, highlighting TAILG’s global appeal.

Frontier Tech and Flagship Products

At the exhibition, TAILG showcased 22 models, including electric motorcycles, e-bikes, electric bicycles, and electric tricycles, meeting diverse mobility needs across global markets.

The F91 Ultra-L fast-charging model made a key appearance, featuring automotive-grade fast-charging technology and an integrated “vehicle + charging station” solution. It offers up to 150 km range and is equipped with a 50,000cd intelligent headlight and a TCS traction control system, delivering balanced performance in power, safety, and lighting.

The upgraded F55 model also attracted attention, featuring a refreshed design and optimized power system, further strengthening its competitiveness in global markets.

Global Presence and Trust

TAILG focuses on real-world mobility needs, optimizing product performance and supply capabilities worldwide. With years of overseas experience, its products have achieved stable performance in markets such as Vietnam, Iraq, and Morocco, supported by expanding distribution networks.

As a partner of the United Nations in electric mobility, TAILG participates in global low-carbon initiatives with international organizations to promote sustainable transport solutions.

Global Strategy

TAILG’s global leadership is built on its integrated R&D, manufacturing, and sales system. The company operates a national-level CNAS laboratory and a global low-carbon mobility research institute, holding over 2,000 patents and multiple international design awards.

It has established seven global R&D and production bases with an annual capacity of over 10 million units, ensuring stable global supply. Its retail network spans more than 27,000 stores across over 70 countries and regions.

Through continuous expansion, TAILG is strengthening its position in the electric mobility industry.

From the Canton Fair, TAILG accelerates global expansion through innovation. Looking ahead, the brand will deepen its global presence, enhance competitiveness, and expand its international market reach.

Debut marks a major milestone in NAVEE’s global expansion and growing focus on U.S. market

MONTEREY, Calif., April 17, 2026 /PRNewswire/ — NAVEE, a global smart mobility brand, announced its official entry into the U.S. e-bike market at the Sea Otter Classic, one of North America’s most influential cycling events. NAVEE introduced eight e-bike series: Urban, Fold, Compa, Speed Pedelec, Bison, Gravel, Storm, and Cyber.

Since 2021, NAVEE has become one of the fastest-growing micro-mobility brands globally, ranking top three in Europe and No. 1 in the Nordic market. Backed by 447 million miles of real-world riding data and over one million riders across 60+ countries, the company is now bringing that same expertise to e-bikes — a strategic move into the U.S. market.

NAVEE is expanding beyond urban commuting into the broader outdoor mobility landscape, with e-bikes at the heart of that evolution. Millions of American riders are embracing new ways to move, from daily commutes to weekend adventures. NAVEE is here to meet that momentum with e-bikes engineered for the way you actually ride.

“Since day one, NAVEE has focused on making everyday mobility easier and more enjoyable through thoughtful design and practical innovation,” said Eric Tian, Head of NAVEE E-bikes. “We see the U.S. as a key growth market and are committed to meeting the everyday needs of riders here.”

Highlighted models at Sea Otter Classic 2026:

Speed Pedelec SP01: Designed for riders who want to go further, faster, with less effort. Delivers 1000W rated power and 100Nm torque for effortless climbing and speeds up to 28mph. Auto-shift transmission adjusts gears automatically.

Gravel Ultra 01: Built for pavement and gravel. Torque sensor technology delivers direct pedal response, while Shimano 10-speed gearing handles the rest.

Bison Core 01: A 48V/750W motor delivers strong acceleration up to 28 mph. Its 20-inch folding frame and puncture-resistant all-terrain tires handle city streets and mixed terrain with ease.

NAVEE also showcased its electric scooter lineup at Sea Otter Classic, including the UT5 Ultra X, UT5 Max, NT5 Ultra X, and GT5 Max — all well received by attendees and demonstrating NAVEE’s full range of smart mobility solutions.

The Storm is now available in the U.S., the Cyber and more models are coming soon. Visit naveetech.us and search “Storm” to learn more.

Media Contact:
Cecilia
NAVEE E-bike PR Manager
wangpeng19@navee.tech

The strategic collaboration brings together METT Singapore’s luxury event spaces, The MasterPlan LLP’s commercial and programme expertise, and UPGroup Asia’s AVL production, technical expertise, and integrated venue operations capabilities to deliver seamless, high-impact events at scale, strengthening the venue’s position in the MICE and premium events landscape.

SINGAPORE, April 18, 2026 /PRNewswire/ — METT Singapore, UPGroup Asia, and The MasterPlan today announced a strategic partnership agreement that brings together the lifestyle hotel’s luxury event spaces with UPGroup Asia’s advanced AVL production capabilities and The MasterPlan LLP’s expertise in high-value business events. The agreement was signed on 17 April 2026 at METT Singapore, 11 Canning Walk, Singapore, during METTUP 2026, a networking event for professionals from the MICE, hospitality and events industries.

Under the partnership, UPGroup Asia joins METT Singapore as its preferred AVL partner, delivering audio, visual, lighting, and livestream production solutions for events at the venue, while activating its Venue Management Programme to elevate the venue’s event operations.

“METT Singapore has the spaces and the character that corporate clients are increasingly looking for. Our role is to make sure the production side is seamless, so that the technical execution never gets in the way of the experience. Having The MasterPlan alongside us means that clients also have access to programme design and stakeholder management expertise from day one. That combination means clients have everything they need to deliver a high-quality event experience, in a venue that is already built for it.”

—  Adam Piperdy, Founder & Chief Experience Officer, UPGroup Asia

The MasterPlan, specialising in business-to-business events including conferences, seminars, product and media launches, C-level meetings, and curating customer experiences, takes on the role of preferred B2B event agency and programme partner, supporting event organisers in designing and executing programmes at METT Singapore.

“Our clients want venues that can deliver on the full promise of an event: the setting, the programme, and the production. METT Singapore gives us that setting, and working alongside UPGroup Asia means the production capability is already in place. For meeting planners and corporate clients looking for a venue that is both distinctive and operationally ready, METT Singapore delivers on both.”

— Jasmine Ho, Founder & Managing Partner, The MasterPlan LLP

The collaboration strengthens METT Singapore’s position as a destination of choice for corporate and MICE events. With UPGroup Asia’s audio, visual, and lighting solutions embedded across its event operations, METT Singapore is equipped to deliver seamless, high-impact experiences at every scale. Through The MasterPlan LLP’s enterprise client relationships and programme expertise, the venue becomes a natural destination for meeting planners, corporate clients, and premium brands seeking a distinctive address for their most important events.

“At METT Singapore, we have always believed in creating spaces that bring people together—thoughtfully designed to foster connection, engagement, and meaningful experiences. Partnering with UPGroup Asia and The MasterPlan LLP allows us to bring this vision to life, combining our environment with the production capabilities and event expertise that today’s corporate and MICE clients expect. We look forward to welcoming more organisations to experience all that METT Singapore has to offer.” 

— Marcel Li, General Manager, METT Singapore

METT Singapore is located within Fort Canning Park and is operated by Sunset Mett Sing Pte. Ltd. under the Sunset Hospitality Group. The hotel features 84 rooms and suites, a 950-square-metre Grand Ballroom and a 360-square-metre Junior Ballroom, alongside outdoor terrace spaces, offering a design-led environment for high-value corporate and luxury events.

ABOUT THE ORGANISATIONS

About UPGroup Asia

UPGroup Asia is an integrated event experience agency delivering event experiences in Singapore and Asia. Empowered by a team of creators, strategists, and experts who are deeply passionate about content, audience engagement, and event technology, UPGroup Asia delivers a complete suite of event solutions that allow event organisers to seamlessly execute award-winning event experiences. Producing hundreds of event experiences for thousands of audiences annually, UPGroup Asia is the trusted partner of both organisations and venue owners in the region.

About The MasterPlan LLP

At The MasterPlan, we specialise in the art of the B2B experience. We take the complexity of conferences, the wow moments at product launches, the prestige of CXO engagements, and the energy of brand activations, and distill them into a single, flawless execution. We cherish long-term partnerships and our clients’ brand and marketing objectives. Thus translating these understandings to great experiences and seamless execution onsite.

About METT Singapore

METT Singapore is a stylish 5-star city escape surrounded by nature that blends elegant colonial charm with contemporary soul. Nestled within the lush, historic grounds of Fort Canning Park, yet steps from Orchard Road, METT presents a destination where heritage meets high energy, social connections are celebrated, and next-generation wellness is embraced.

The iconic listed property, which celebrates its 100th anniversary this year offers 84 elegant and light-filled suites and rooms and bespoke event spaces designed to inspire unforgettable moments. At the heart of the experience is dining as a social ritual led by Michelin-starred Chef Daniele Sperindio, offering four distinctive concepts including L’Amo Bistrò del Mare, an ode to premium Italian coastal dining.

Hotel guests enjoy access to Madison House private members club, with two sparkling swimming pools, three padel and pickleball courts, a state-of-the-art fitness studio and wellness by The Longevity Suite.

MEDIA CONTACTS

UPGroup Asia
Josiah Eufemio  |  Marketing & Communications Lead  |  josiah_eufemio@upgroup.asia

The MasterPlan LLP
Laiyee Wong  |  Senior Project Manager  |  laiyee@themasterplan.com.sg

METT Singapore
Glenda Raphaela Dharma | Assistant Marketing Manager – Hotel | glenda.dharma@metthotelsandresorts.com

SHANGHAI and HONG KONG, April 18, 2026 /PRNewswire/ — Antengene Corporation Limited  (“Antengene”, SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, today announced that it has released present results from three novel programs in poster presentations at the 2026 American Association for Cancer Research Annual Meeting (AACR 2026). The presentations will feature ATG-125 (B7-H3 x PD-L1 bispecific antibody-drug conjugate [ADC]), an IO + ADC dual-function molecule being developed for the treatment of solid tumors, as well as two investigational T cell engagers (TCEs) developed using the company’s proprietary AnTenGager^® TCE platform, including ATG-106 (CDH6 x CD3 TCE) for ovarian and kidney cancers, and ATG-112 (ALPPL2 x CD3 TCE) for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC.

Details of the Poster Presentation:
ATG-125 (B7-H3 x PD-L1 bispecific ADC)
Title: ATG-125, a novel B7H3 x PD-L1 bispecific antibody-drug conjugate, demonstrates potent antitumor efficacy by dual targeting of immune evasion and direct tumor killing
Abstract Number: 5599
Session Category: Immunology
Session Title: T Cell Engagers 2 / Antibody-Drug Conjugates 1
Date: April 21, 2026
Time: 02:00 PM – 05:00 PM (Pacific Time)
           05:00 AM, April 22, 2026 – 08:00 AM, April 22, 2026 (Beijing Time)
Location: Poster Section 8

• Introduction: B7-H3 and PD-L1 are immune checkpoint molecules broadly overexpressed across multiple solid tumors and are associated with immune evasion and poor prognosis. Although PD-1/PD-L1-directed therapies have demonstrated clinical benefit, treatment resistance remains a significant challenge. B7-H3 is also emerging as a promising ADC target due to its broad tumor expression and rapid internalization. ATG-125 is a novel B7-H3 x PD-L1 bispecific ADC designed to combine direct tumor killing with immune activation by co-targeting two complementary tumor-associated pathways in a single molecule.
• Results: ATG-125 bound to both B7-H3 and PD-L1 with high specificity and nanomolar affinity and demonstrated robust antigen-dependent internalization in dual-positive tumor cells, enabling efficient intracellular payload release. The molecule induced tumor cell apoptosis, while its parental naked antibody blocked PD-1/PD-L1 interaction and elicited IL-2 and IFN-γ production in mixed lymphocyte reaction assays. ATG-125 also enhanced T-cell activation, as reflected by an increased ratio of CD69+/CD3+ T cells in co-cultures of tumor cells and human PBMCs. In vivo, ATG-125 demonstrated sustained antitumor activity in HCC827 xenograft models, increased tumor infiltration of CD4+ and CD8+ T cells in PBMC-humanized models, and inhibited tumor growth in a dose-dependent manner in MC38-hB7H3 syngeneic models, accompanied by elevated intratumoral CD8+ T-cell infiltration.
• Conclusion: ATG-125 demonstrated synergistic IO+ADC antitumor activity through a differentiated mechanism combining enhanced internalization for payload delivery with the potential to restore anti-tumor immunity. Its compelling preclinical profile supports further development for patients with solid tumors.

ATG-106 (CDH6 x CD3 TCE)
Title: ATG-106, a novel “2+1” format CDH6-targeted T-cell Engager (TCE), shows potent T cell dependent cytotoxicity and in vivo anti-tumor efficacy
Abstract Number: 1621
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: CDH6 plays an important role in embryonic kidney development but has negligible expression in adult kidney tissue. Its overexpression in ovarian and renal cancers, together with limited normal tissue expression, makes CDH6 an attractive therapeutic target. However, T cell engagers in solid tumors have often been limited by insufficient efficacy and the risk of cytokine release syndrome. To address these challenges, Antengene developed ATG-106, a novel “2+1”, sterically masked CDH6 x CD3 bispecific TCE designed to deliver potent antitumor activity with the potential for a reduced CRS risk profile.
• Results: ATG-106 exhibited reduced binding affinity to CD3+ cells before CDH6 crosslinking, while inducing approximately 100- to 400-fold more potent cytotoxicity against CDH6-positive tumor cells compared with a “1+1” CrossMab control TCE. The molecule demonstrated potent T cell-dependent cytotoxicity in ovarian and renal cancer models and showed low immunogenicity risk in vitro. In PBMC-humanized 786-O kidney cancer xenograft models, ATG-106 induced tumor shrinkage in all treated mice, with complete remissions observed in the 0.1 mg/kg and 0.3 mg/kg groups. ATG-106 also induced tumor shrinkage and complete remission in PBMC-humanized OVCAR-3 ovarian cancer models. Notably, pro-inflammatory cytokine levels remained very low in treated animals, suggesting low CRS risk. In non-human primate studies, the surrogate molecule ATG-106-RM was well tolerated at doses up to 10 mg/kg.
• Conclusion: ATG-106 demonstrated limited T cell binding in the absence of target cells, potent cytotoxicity against tumor cells, and encouraging in vivo efficacy in ovarian and kidney cancer models. Favorable safety findings with the surrogate molecule in non-human primates further support continued clinical development of ATG-106 as a CDH6-targeted TCE candidate.

ATG-112 (ALPPL2 x CD3 TCE)
Title: ATG-112, a novel ALPP/G x CD3 bispecific T cell engager, for the treatment of ALPP/G⁺ solid tumors
Abstract Number: 1620
Session Category: Immunology
Session Title: T Cell Engagers 1
Date: April 20, 2026
Time: 09:00 AM – 12:00 PM (Pacific Time)
           00:00 AM, April 21, 2026 – 03:00 AM, April 21, 2026 (Beijing Time)
Location: Poster Section 10

• Introduction: Placental alkaline phosphatase and related placental-like/germ-cell isoforms, including ALPPL2 and ALPG, are aberrantly expressed in a range of solid tumors while being largely absent from normal adult tissues except the placenta, making them highly promising tumor-selective immunotherapy targets. Antengene developed ATG-112, an ALPP/G x CD3 bispecific TCE based on the AnTenGager^® platform in a “2+1” format, featuring bivalent antigen binding to improve low-antigen tumor recognition and a sterically masked CD3 binding arm designed to restrict T-cell activation to the tumor microenvironment.
• Results: Tissue microarray IHC analysis showed that ALPP/G expression was restricted to placental tissue among normal organs and was not detected in other normal tissues, while frequent expression was observed in endometrial and ovarian cancers, with lower prevalence in bladder, gastric and pancreatic cancers. ATG-112 demonstrated high binding affinity to both ALPP/G-positive tumor cells and recombinant proteins, with EC50 and KD values in the sub-nanomolar range. It induced robust T cell-dependent cytotoxicity against target-positive cells with picomolar EC50 values, while in vitro cytokine-release assays showed minimal cytokine secretion from human PBMCs. In vitro studies also demonstrated that the spatial masking effect of ATG-112 is reversible. Immunogenicity assessment showed low immunogenic potential, and in vivo ATG-112 delivered potent tumor suppression across multiple dose levels in humanized mouse models, with low cytokine release and controllable CRS risk at efficacious doses. The program also demonstrated strong developability characteristics.
• Conclusion: ATG-112 demonstrated a compelling preclinical profile, with potent in vitro and in vivo antitumor activity and minimal cytokine release. These findings support the continued advancement of ATG-112 toward clinical development for solid tumors.

About Antengene
Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages and includes several in-house discovered programs, including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), and ATG-125 (B7-H3 × PD-L1 bispecific ADC).

Antengene has also developed AnTenGager^®, a proprietary T cell engager 2.0 platform featuring “2+1” bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform’s broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 32 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO^® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements
The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company’s Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: donald.lung@antengene.com  

BD Contacts:
Ariel Guo
E-mail: ariel.guo@antengene.com